



PGX-HIV StripAssay[®]

The easy way to optimize highly active antiretroviral therapy (HAART) using established innovations in diagnostics

**PGX-HIV Assay.
Key to efficient therapy.**

Highly active antiviral therapy (HAART), the combined use of different types of antiretroviral drugs, can efficiently combat AIDS. HAART works most effectively, and side effects can be minimized when genetic variations of the individual patient are taken into account.

Genetic parameters of the individual patient contribute to differences in the response to HAART. Such factors affect the uptake or inactivation of HAART components and include allelic variants of the multidrug transporter P-glycoprotein 1 (MDR1), cytochrome P450 isozyme 2D6 (CYP2D6) and the C-C chemokine receptor 5 (CCR5).

ViennaLab's PGX-HIV StripAssay[®] offers an easy way to identify the most relevant genetic variations influencing highly active antiretroviral therapy (HAART).

Gene	Relevance for HAART	Status	Effect
MDR1	Multidrug resistance	wildtype	Normal immunorecovery and decrease of viral load
		variant	Improved immunorecovery and decrease of viral load
CYP2D6	Drug metabolization	wildtype	Normal drug turnover
		variant	Slow drug turnover
CCR5	Cellular entry of HIV	wildtype	Normal therapy response
		variant	Improved therapy response

The Assay

ViennaLab's PGX-HIV StripAssay® meets customer requirements

Requirement	ViennaLab's offer
Easy	Three simple steps. 6 h. Done.
Reliable	Can be automated. Probes for variants and controls combined on one teststrip.
Versatile	Effective genotyping of DNA from various sample types.
Affordable	Reagents. Thermocycler. Incubator. That is all you need. A software is optional.

ViennaLab's PGX-HIV StripAssay®

- is based on reverse-hybridization of biotinylated PCR products
- combines probes for variants and controls in a parallel array of allele-specific oligonucleotides
- works with immobilized oligos on a teststrip
- generates test results by enzymatic color reaction easily visible to the naked eye

Genetic Variants detected

MDR1 (3435 C>T), *CYP2D6* (*3/*4/*6) and *CCR5* (32 bp deletion)

The three steps of ViennaLab's PGX-HIV StripAssay®

Step	Requirement
1. Amplification: Multiplex PCR-amplification. Simultaneous biotin-labeling	Thermocycler
2. Hybridization: Directly on the StripAssay® teststrips	Incubator
3. Identification: Labeled products detected by streptavidin-alkaline phosphatase	Naked eye or scanner & software

Cat.no.: PGX-HIV StripAssay®: 4-710 (20 tests/kit)

ViennaLab offers StripAssays® for a wide range of diagnostic applications. Visit www.viennalab.com

Manufacturer:
ViennaLab Diagnostics GmbH
Gaudenzdorfer Gürtel 43-45
A-1120 Vienna, Austria
Phone: (+43-1) 8120156-0
Fax: (+43-1) 8120156-19
info@viennalab.com

Distributor:



More details available at www.viennalab.com